Abbokinase (Urokinase) - Summary

ABBOKINASE SUMMARY

Abbokinase® (urokinase) is a thrombolytic agent obtained from human neonatal kidney cells grown in tissue culture.

Abbokinase® is indicated in adults:

• For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments.
• For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures.

The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning.

See all indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Abbokinase (Urokinase)

Program Cuts Excess Radiation Exposure (CME/CE)
Source: MedPage Today Radiology [2010.01.22]
A New York medical center substantially reduced diagnostic radiation doses with an education program and clinical algorithm to promote ventilation-perfusion scanning in lieu of CT pulmonary angiography for detecting pulmonary embolism, researchers said.

more news >>

Published Studies Related to Abbokinase (Urokinase)

Percutaneous treatment of intrabdominal abscess: urokinase versus saline serum in 100 cases using two surgical scoring systems in a randomized trial. [2009.07]
The purpose of this study was to assess whether regular instillation of urokinase during abscess drainage leads to an improved outcome compared to saline irrigation alone. One hundred patients referred for image-guided abdominal abscess drainage were randomized between thrice daily urokinase instillation or saline irrigation alone...

Use of urokinase in percutaneous drainage of large breast abscesses. [2009.04]
OBJECTIVE: The purpose of this study was to evaluate intracavitary urokinase therapy versus irrigation with a saline solution in percutaneous drainage of large breast abscesses... CONCLUSIONS: Percutaneous drainage of large breast abscesses in nonlactating women with intracavitary urokinase irrigation is a simple and safe procedure. It reduces the treatment time and improves the clinical course of patients more than conventional drainage with saline irrigation.

Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. [2008.09]
Patients with diabetic foot ulceration and critical limb ischemia have a high risk of major amputation, especially if limbs can not be revascularized...

Prevention of coagulase-negative staphylococcal central venous catheter-related infection using urokinase rinses: a randomized double-blind controlled trial in patients with hematologic malignancies. [2008.01.20]
PURPOSE: Fibrin deposition at the intraluminal surface of the indwelling part of the central venous catheter (CVC) surface increases the risk of CVC-related coagulase-negative staphylococci (CoNS) infection. Therefore, repetitive enzymatic dissolution of fibrin by urokinase might reduce the risk of CVC-related infection. We undertook this study to investigate whether three times weekly urokinase rinsing of CVC reduces the incidence or severity of CVC-related infections by CoNS in patients undergoing intensive cytotoxic treatment for hematologic malignancies... CONCLUSION: Three times weekly urokinase rinsing reduces the incidence of CVC-related CoNS infection in patients treated with intensive cytotoxic therapy for hematologic malignancies, with acceptable safety.

Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke: the middle cerebral artery embolism local fibrinolytic intervention trial (MELT) Japan. [2007.10]
BACKGROUND AND PURPOSE: The Middle Cerebral Artery Embolism Local Fibrinolytic Intervention Trial (MELT) Japan was organized to determine the safety and clinical efficacy of intraarterial infusion of urokinase (UK) in patients with stroke within 6 hours of onset... CONCLUSIONS: The trial was aborted prematurely and the primary end point did not reach statistical significance. Nevertheless, the secondary analyses suggested that intraarterial fibrinolysis has the potential to increase the likelihood of excellent functional outcome.

more studies >>

Clinical Trials Related to Abbokinase (Urokinase)

Urokinase Therapy in Diabetic Foot Syndrome [Completed]
The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000 000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in patients with diabetic foot syndrome.

Dornase Alfa and Urokinase for Kids With Pleural Empyema [Recruiting]
The purpose of this study is to determine whether intrapleural treatment with Dornase alfa plus Urokinase improves clinical outcome compared to Urokinase alone in children with complicated parapneumonic effusions

Urokinase Versus Video-Assisted Thoracoscopic to Treat Complicated Parapneumonic Empyema in Childhood [Recruiting]
A great controversy exists about which is the best method to perform the evacuation of the collection. To evaluate which is the best initial treatment to drain complicated parapneumonic empyema (stages II and III) in children: the present study raises a hypothesis of equivalence between both arms of treatment (chest drainage plus intrapleural urokinase or videothoracoscopic debridement).

Urokinase Therapy in Patients With Diabetic Foot Syndrome [Recruiting]
The purpose of this study is to determine whether the additional therapy with low dose urokinase is more effective than only a conventional standard therapy concerning ulcer-healing, rate of major amputation and survival.

Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia [Active, not recruiting]
We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.

more trials >>